CD274 and cervical carcinoma: PD-L1 is one of the biomarkers currently approved for clinical use, but only to identify PD-L1 tumor expression in certain tumor types, specifically in: NSCLC for treatment with pembrolizumab, cemiplimab, atezolizumab or nivolumab in combination with ipilimumab; urothelial carcinoma and triple-negative breast cancer (TNBC) for treatment with pembrolizumab, cemiplimab or atezolizumab; and gastric adenocarcinoma, cervical cancer, head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma for treatment with pembrolizumab or cemiplimab [45].